DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Harren Jhoti, Ph.D., president, will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12th in New York as Astex Pharmaceuticals, Inc., subject to final legal and NASDAQ listing approvals.
The Company's presentation will begin at 11:40 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website. The webcast will be archived for 30 days.
About SuperGen
SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. SuperGen developed Dacogen® and receives significant royalties on global sales.
For more information about SuperGen, please visit http://www.supergen.com.
Note on Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to, statements regarding the expectation that the Company will change its name and ticker symbol. These and other forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but not limited to, the ability of the Company to change its name and its ticker symbol, and such other risks as identified in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, and the Company’s most recent Quarterly Reports on Form 10-Q, each as filed with the SEC, which contain and identify important factors that could cause the actual results to differ materially from those contained in the forward-looking statements. The Company assumes no obligation to update any forward-looking statement contained in this press release.
CONTACT:
SuperGen, Inc.
Timothy L. Enns, (925) 560-2810
Senior Vice President
Corporate Communications & Business Dev.
[email protected]
or
SuperGen, Inc.
Susanna Chau, (925) 560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, (646) 378-2945
Managing Director
[email protected]
or
Fleishman-Hillard
Michael Ares, (404) 739-0133
Senior Vice President
[email protected]
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA:
| Logo |